You have read all your free articles, to continue reading subscribe to read the rest of this content.
This dual listing will further enable the advance its two innovative programs: CDNF in Parkinson’s Disease and drug candidate, Lymfactin, in Lymphedema. As part of the offering Herantis issued a total of 618,018 new shares at a price of €6.72 EUR / SEK 71 per share bringing the total number…
AstraZeneca and Daiichi Sankyo have received notification of acceptance of the supplemental Biologics License Application (sBLA) of Enhertu for the treatment of adult patients in the US with unresectable or metastatic HER2-positive breast cancer who have received a prior anti-HER2-based regimen. Already a subscriber Login You have read all your…
Genmab and Seattle Genetics announces that Seattle Genetics has exercised its option to co-develop tisotumab vedotin. The companies originally entered into a commercial license and collaboration agreement in October 2011 under which Seattle Genetics had the right to exercise a co-development optiAlready a subscriber Login You have read all your…
Farxiga (dapagliflozin) has been granted Breakthrough Therapy Designation (BTD) in the US for patients with chronic kidney disease (CKD), with and without type-2 diabetes (T2D). The Food and Drug Administration (FDA)'s BTD is designed to accelerate the development and regulatory review of potentiAlready a subscriber Login You have read all…
